Henry Schein Stock (NASDAQ:HSIC), Trade Ideas

Henry Schein

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

nvidia chart shutter2

Analyst Color

Equities

News

Markets

Tech

General

CBOE

CTSH

HSIC

NVDA

The analysis screened S&amp;P 500 stocks that show an inverse correlation to Nvidia over a month and year period, following Nvidia&#39;s stock falling into correction territory for the second time this month.

Jack Daniels Parent Company, EA, Cognizant Among 6 Stocks That Shine When Nvidia Slips: Analysis

European,Young,Woman,Smiling,While,Looking,At,Mirror,In,Dental

Earnings

Large Cap

Guidance

Health Care

Reiteration

Analyst Ratings

Henry Schein reports fourth quarter 2023 sales at $3.02 billion. Despite cybersecurity challenges, William Blair is optimistic.

Cybersecurity Incident Casts Shadow On Henry Schein&#39;s Q4 Performance, Analysts Optimistic On Dental Sector

What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition

Biotech

Penny Stocks

Small Cap

AMPH

NATR

STEK

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion dollar business, projected to hit a market size of $98 billion in less than a decade.

Henry Schein Inc

Six S&amp;P 500 stocks often experience a surge when shares of Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) take a dip, an analysis by CNBC revealed.
What Happened: The six U.S.-listed stocks that typically see a rise when Nvidia&#8217;s shares falter include Jack Daniel's distiller Brown-Forman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>), gaming giant Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), health products manufacturer Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), software outsourcing behemoth Cognizant Technology Solutions Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), pet care company Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), and securities exchange Cboe Global Markets, Inc. (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>), CNBC <a href="https://www.cnbc.com/2024/04/19/here-are-the-6-stocks-that-rise-when-nvidia-shares-fall.html">reported</a> on Thursday.
The Pearson correlation coefficient, a measure of linear correlation between two variables, was used in the analysis to determine the relationship between the stock prices. The analysis screened S&amp;P 500 stocks that show an inverse correlation to Nvidia over a month and year period, following Nvidia&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38177926/whats-next-for-nvidia-as-stock-enters-correction-zone-munster-singles-out-crucial-q">stock falling into correction territory</a> for the second time this month. 
Some technical analysts have suggested that it might be time for investors to offload Nvidia too. Katie Stockton of Fairlead Strategies noted that chart patterns suggest a deeper pullback might be on the horizon "just in time for the seasonal adage of ‘sell in May, and go away' to manifest itself in investor behavior." 
See Also: <a href="https://www.benzinga.com/news/24/04/38286752/elon-musk-reacts-as-marc-andreessen-says-google-is-literally-run-by-employee-mobs-with-chinese-spies?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts As Marc Andreessen Says Google Is &#8216;Literally Run By Employee Mobs&#8217; With &#8216;Chinese Spies&#8217;</a>
Adam Parker of Trivariate Research also listed eight steady growth stocks that could replace Nvidia if investors are worried about overexposure.
Why It Matters: Nvidia&#8217;s stock has been in the spotlight recently. In April, Evercore ISI predicted that <a href="https://www.benzinga.com/markets/equities/24/04/38306414/nvidia-stock-could-see-81-upside-by-2025-says-evercore-isi-only-in-the-beginning-phases-of-gener">Nvidia&#8217;s stock could surge by 81% by 2025</a>, suggesting that the company was only in the initial stages of generating outsized returns. 
However, the stock has been under pressure due to concerns over rising interest rates and a slew of corporate earnings reports. This led to <a href="https://www.benzinga.com/top-stories/24/04/38313015/nvidia-etfs-take-center-stage-as-bears-bulls-duke-it-out-with-8-14-swings">significant swings in Nvidia ETFs</a> as bulls and bears battled it out. 
As of Thursday, Nvidia&#8217;s stock closed at $846.71, marking an increase of 0.76% from the previous close. The stock&#8217;s 52-week high and low are $974 and $262.25 respectively, indicating significant fluctuations in the stock&#8217;s performance.
Read Next: <a href="https://www.benzinga.com/news/24/04/38111017/tesla-ceo-elon-musk-disagrees-with-nvidias-jensen-huang-that-anyone-can-make-their-own-neural-networ?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Disagrees With Nvidia&#8217;s Jensen Huang That Anyone Can Make Their Own Neural Network: &#8216;It&#8217;s Insanely Hard&#8217;</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

JP Morgan analyst Rachel Vatnsdal maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Overweight and raises the price target from $82 to $88.

Price Target

JP Morgan Maintains Overweight on Henry Schein, Raises Price Target to $88

Jefferies analyst Brandon Couillard maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Hold and raises the price target from $74 to $81.

Jefferies Maintains Hold on Henry Schein, Raises Price Target to $81

Henry Schein's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) short percent of float has risen 4.03% since its last report. The company recently reported that it has 5.23 million shares sold short, which is 4.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Henry Schein Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709321412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Henry Schein has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Henry Schein's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Henry Schein's peer group average for short interest as a percentage of float is 4.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(HSIC) - Analyzing Henry Schein's Short Interest

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $83.8, a high estimate of $90.00, and a low estimate of $78.00. This current average has increased by 8.13% from the previous average price target of $77.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1709150430_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Henry Schein among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$83.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Henry Schein. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Henry Schein's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Henry Schein's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Henry Schein analyst ratings.</a>
<h2>All You Need to Know About Henry Schein</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Henry Schein's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Henry Schein's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.1% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Henry Schein's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Henry Schein's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.45%, the company showcases efficient use of assets and strong financial health.
Debt Management: Henry Schein's debt-to-equity ratio is below the industry average. With a ratio of 0.63, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Henry Schein: What You Need To Know

Evercore ISI Group analyst Ross Muken maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a In-Line and raises the price target from $79 to $83.

Evercore ISI Group Maintains In-Line on Henry Schein, Raises Price Target to $83

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and raises the price target from $82 to $90.

Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $90

Dental supply company Henry Schein Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported fourth-quarter 2023 sales of $3.02 billion, slightly missing the consensus of $3.04 billion, <a href="https://www.benzinga.com/calendars/earnings">down 10.5% year-over-year</a>.
This reflects an internal sales decrease of 12%, calculated at constant foreign exchange rates
Total net sales reflect an estimated reduction of $350 million to $400 million, or 10% to 12%, due to the cybersecurity incident.
&#8220;Our fourth quarter financial results included strong growth in our Technology and Value-Added Services businesses, and in global sales of implants and biomaterials largely driven by acquisitions, and were negatively impacted by higher-than-usual acquisition-related expenses and adjustments,&#8221; Stanley M. Bergman, Chairman of the Board and CEO.
Global Dental sales were $1.8 billion, down 10.9% Y/Y, driven by merchandise sales down 11.3% and equipment down 9.7%. Global Medical sales were $1 billion, <a href="https://www.benzinga.com/pressreleases/24/02/b37329830/henry-schein-reports-fourth-quarter-and-full-year-2023-financial-results-and-introduces-2024-finan" target="_blank" rel="noreferrer noopener">down 17% Y/Y</a>.
Adjusted EPS of 66 cents, down 51% Y/Y, missing the consensus estimate of 70 cents.
Guidance: Henry Schein forecasts fiscal year 2024 adjusted EPS of $5.00-$5.16, versus the consensus of $5.10. The guidance includes an estimated residual impact of the cybersecurity incident of approximately 15 cents per diluted share, which will primarily impact the first quarter.
For 2024, sales growth is expected to be approximately 8% to 12% over 2023 and reflects the expected merchandise sales recovery after the cybersecurity incident and sales from the acquisitions completed in 2023.
2024 Adjusted EBITDA is expected to increase by more than 15%.
William Blair&nbsp;says the recent cybersecurity attack in late 2023 has clouded the assessment of momentum within the dental segments.&nbsp;
However, the quarter&#8217;s performance surpassed expectations, instilling optimism for the dental sector in 2024.&nbsp;
The only setback appears to be a 2% shortfall in global medical sales, with limited details provided in the release.&nbsp;
Despite challenges such as tax issues and cybersecurity threats, the company&#8217;s solid performance is evident in the full-year 2024 EPS guidance, which aligns with or exceeds Street expectations.&nbsp;
This suggests a promising outlook for the company to achieve high-single-digit-plus growth.
William Blair keeps the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/HSIC/analyst-ratings" rel="noreferrer noopener">Market Perform rating</a>.
Price Action:&nbsp;HSIC stock is up 0.13% at $80.30 on the last check Tuesday.
Now Read: <a href="https://www.benzinga.com/24/02/37331610/7-growth-for-us-cathie-woods-ark-invest-sees-future-far-rosier-than-consensus-view-thanks-to-ai-bloc">7% Growth For US? Cathie Wood&#8217;s Ark Invest Sees Future Far Rosier Than Consensus View Thanks To AI, Blockchain And Other Transformational Tech</a>
Image: Shutterstock

Cybersecurity Incident Casts Shadow On Henry Schein's Q4 Performance, Analysts Optimistic On Dental Sector

WIIM

Henry Schein shares are trading lower after the company reported worse than expected Q4 FY2023 earnings and issued 2024 guidance.

Henry Schein Expects Fiscal Year 2024 Sales Growth To Be Approximately 8% To 12% Over 2023

Henry Schein Forecasts Fiscal Year 2024 Adjusted EPS Of $5.00-$5.16 Versus Consensus Of $5.10

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $0.66 per share which missed the analyst consensus estimate of $0.70 by 5.71 percent. This is a 51.11 percent decrease over earnings of $1.35 per share from the same period last year. The company reported quarterly sales of $3.02 billion which missed the analyst consensus estimate of $3.04 billion by 0.76 percent. This is a 10.50 percent decrease over sales of $3.37 billion the same period last year.

Henry Schein Q4 Adjusted EPS $0.66 Misses $0.70 Estimate, Sales $3.02B Miss $3.04B Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.
Analysts estimate that Henry Schein will report an earnings per share (EPS) of $0.70. 
Henry Schein bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 2.07% increase in the share price the next day.
Here's a look at Henry Schein's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.32</td>
<td>1.25</td>
<td>1.23</td>
<td>1.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.31</td>
<td>1.21</td>
<td>1.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708959728_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Henry Schein were trading at $79.86 as of February 23. Over the last 52-week period, shares are up 3.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HSIC/earnings">To track all earnings releases for Henry Schein visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Henry Schein Earnings Preview

Piper Sandler analyst Jason Bednar maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Overweight and raises the price target from $78 to $86.

Piper Sandler Maintains Overweight on Henry Schein, Raises Price Target to $86

Leerink Partners analyst Michael Cherny initiates coverage on Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Market Perform rating and announces Price Target of $78.

Initiation

Leerink Partners Initiates Coverage On Henry Schein with Market Perform Rating, Announces Price Target of $78

Henry Schein's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) short percent of float has risen 3.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 3.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Henry Schein Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1707338717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Henry Schein has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Henry Schein's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Henry Schein's peer group average for short interest as a percentage of float is 4.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Henry Schein's Recent Short Interest

Henry Schein One Announced That 42 North Dental Is Implementing The Full Range Of Its Cloud-Based Platform Including Dentrix Ascend, Jarvis Analytics, TechCentral And Its AI-Enabled X-ray Analysis Tool, Detect AI

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It&rsquo;s no wonder vitamin supplements are a multi-billion dollar business, projected to hit a market size of <a href="https://www.alliedmarketresearch.com/press-release/vitamin-supplements-market.html">$98 billion</a> in less than a decade. While vitamin supplements have been around since the early 1900s, it wasn&rsquo;t until the late 1950s that they took off with the masses as consumers adopted healthier lifestyles and awareness grew about their benefits.
Today, there are vitamins for everything from improving gut health to slowing aging. A survey conducted in 2019 found that more than <a href="https://osteopathic.org/2019/01/16/poll-finds-86-of-americans-take-vitamins-or-supplements-yet-only-21-have-a-confirmed-nutritional-deficiency/">four in five Americans take vitamins or supplements</a>.&nbsp;&nbsp;
The regenerative wellness sector may be following a similar trajectory, where stem cells are playing a leading role in wellness and anti-aging thanks to their self-renewal ability. Stem cells have the potential to <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276428/#:~:text=Adipose%2Dderived%20mesenchymal%20stem%20cells&amp;text=In%20terms%20of%20anti%2Daging,cell%20regeneration%20through%20paracrine%20action.">regenerate cells, tissues and organs</a> in the body, improving people&rsquo;s quality of life and slowing the aging process. Studies have shown the more stem cells you have circulating in your blood, the greater the ability of your body to renew itself &ndash; naturally.
<h3>Stem Cells Turn Back The Clock&nbsp;</h3>
Stem cells&rsquo; rejuvenating abilities are already making it a big business, one that seems poised for more growth in the years to come, following in the footsteps of the vitamin industry. The stem cell market is projected to hit <a href="https://www.visionresearchreports.com/stem-cells-market/39760">$32 billion by 2030</a>, growing at a CAGR of 11.57%. That compares to the global vitamin supplements market which <a href="https://www.alliedmarketresearch.com/vitamin-supplements-market-A16898#:~:text=Vitamin%20Supplements%20Market%20Research%2C%202031,7.6%25%20from%202022%20to%202031.">reached $47.9 billion in 2021</a> and is projected to hit $98.6 billion by 2031, growing at a CAGR of 7.6%. In its early days, the vitamin supplements market had double-digit growth, similar to what the stem cell market is seeing.&nbsp;
One company planning to ride this burgeoning trend is Stemtech Corporation (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/stek#OTCQB">STEK</a>), the <a href="https://www.stemtech.com/us">Naples, Florida company</a> that develops science-based products to support wellness using the body&rsquo;s own stem cells. Stemtech says its stem cell enhancers improve the body&rsquo;s natural defense, renewal, rejuvenation and anti-aging processes. Its products also boast powerful anti-aging components, which is proving popular with its many loyal customers. The company reports that sales are steadily increasing quarter over quarter and more of the same is expected in 2024. That growth is being driven by demand for its products and its network of distributors known as Independent Business Partners (IBPs) eager to sell Stemtech&rsquo;s stem cell-based supplements. &quot;Stemtech is witnessing the increase in the number of our IBP Independent Business Partners network. This positive momentum is a testament to the appeal of Stemtech&#39;s exceptional anti-aging products and the promising income-earning opportunity we offer,&quot; Stemtech President and COO John W. Meyer said <a href="https://www.stemtech.com/us/Company/Investors?subnav=NAM">in a recent press release</a>.&nbsp;
Stemtech isn&rsquo;t the only player in the stem cell market, several transformative health companies are going after different areas including Sprouts Farmers Market (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfm#NASDAQ">SFM</a>), Amphastar Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amph#NASDAQ">AMPH</a>), OPKO Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>), Herbalife Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NASDAQ">HLF</a>), Natural Grocers by Vitamin Cottage Inc. (NGVC), Nature&#39;s Sunshine Products Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/natr#NASDAQ">NATR</a>) and Henry Schein Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsic#NASDAQ">HSIC</a>).
<h3>Stemtech&rsquo;s Edge</h3>
Thanks to the science its approach is based on, Stemtech believes it has an edge over other players in the stem cell enhancing market. Stemrelease3&trade;, Stemtech&rsquo;s most advanced stem cell nutrition product, contains stemrelease3, a blend of clinically tested ingredients that Stemtech says help release millions of your body&rsquo;s own stem cells from the bone marrow into the bloodstream. The company says stemrelease3 also helps support telomere health, which is a potent defense to the aging process.&nbsp;
<a href="https://www.stemtech.com/us/Products/RCM">The RCM System, its flagship</a> system, is comprised of three products: Stemrelease3&trade;, StemFlo Advanced&reg; and MigraStem&trade; also containing superfood extracts, antioxidants, polysaccharides, vitamins, minerals and other natural compounds. These are designed to support the healthy activity of our stem cells and boost the immune and circulatory system functions. The nutrients in RCM also help to activate the energy processes in the mitochondria, have antioxidant and detoxification effects and support telomere health, according to Stemtech.&nbsp;
&nbsp;
Stemtech&rsquo;s <a href="https://www.stemtech.com/us/Products/CellectOne">Cellect One&trade; Rapid Renew Stem Cell Peptide Night Cream</a> is another product the company reports is popular. It uses patented ingredient QXP from Red Oak Bark to lower the skin&#39;s barriers so stem cells and peptides containing antioxidants and proteins can penetrate deeper into the skin, assisting in improving skin moisture, elasticity and a more youthful look.
The company also offers OraStem&reg;, an all-natural toothpaste that protects, strengthens, rejuvenates, restores and supports your teeth and gum function from the cellular level. In addition, Stemtech says it also provides anti-oxidative and anti-microbial protection, supports your tooth strength with essential minerals, helps to gently remove stains, brightens your teeth in a natural and non-abrasive way and freshens breath.
Stemtech&rsquo;s line of supplements, skin care products and oral care products aims to answer a need among consumers for anti-aging and wellness products that actually work. What vitamins did for healthy living, stem cells can do for aging. Stemtech is planning to take center stage in this evolution, betting it can play a big role in rejuvenating the body and turning back the clock one stem cell at a time.&nbsp;
Featured photo by <a href="https://unsplash.com/@cdc?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">CDC</a> on <a href="https://unsplash.com/photos/woman-holding-laboratory-appratus-LiNIONbajm4?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Disclaimer: This announcement contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as &quot;believes,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;estimates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;targets,&quot; &quot;projects&quot; and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company&#39;s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on December 1, 2023. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
&nbsp;

TriMed had 2022 net sales of approximately&nbsp;$48 million. The transaction is subject to certain regulatory approvals and closing conditions, and is expected to be completed in the&nbsp;first quarter&nbsp;of 2024

Henry Schein Has Agreed To Acquire A Majority Interest In TriMed, A Developer Of Solutions For Orthopedic Treatment Of Lower Extremities (Foot And Ankle) And Upper Extremities (Primarily Hand And Wrist); Deal Terms Were Not Disclosed

Despite Disappointing Results, Henry Schein Looks Appealing Moving Forward

Henry Schein, Inc. (HSIC) receives a weak  valuation ranking of 34 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. HSIC has a better value than 34% of stocks based on these valuation analytics.

Should You Buy Henry Schein, Inc. (HSIC) Stock Wednesday?

Tracking Al Gore's Generation Investment Management Portfolio - Q4 2023 Update

InvestorsObserver is giving Henry Schein, Inc. (HSIC) an Analyst Rating Rank of 18, meaning HSIC is ranked higher by analysts than 18% of stocks. The average price target for HSIC is $80.09 and analystâ€&#x2122;s rate the stock as a Buy. Wall Street analysts are rating HSIC a Buy today.  Find out what this means to you and get the

What is Wall Street's Target Price for Henry Schein, Inc. (HSIC) Stock Wednesday?

Overall market sentiment has been neutral on Henry Schein, Inc. (HSIC)  stock lately. HSIC receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator. Henry Schein, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on HSIC!See Full HSIC ReportWhat is Sto

Is Henry Schein, Inc. (HSIC) Stock About to Get Hot Thursday?

Henry Schein, Inc. (HSIC) is near the middle in its industry group according to InvestorsObserver. HSIC gets an overall rating of 52. That means it scores higher than 52 percent of stocks. Henry Schein, Inc. gets a 38 rank in the Medical Distribution industry. Medical Distribution is number 4 out of 148 industries. HSIC ha

Where Does Henry Schein, Inc. (HSIC) Stock Fall in the Medical Distribution Field After It Is Down -0.55% This Week?

The 42 rating InvestorsObserver gives to Henry Schein, Inc. (HSIC)  stock puts it near the middle of the Healthcare sector.In addition to scoring higher than 59 percent of stocks in the Healthcare sector, HSIC's 42 overall rating means the stock scores better than 42 of all stocks. HSIC has an Overall Score of 42. Find out

Will Henry Schein, Inc. (HSIC) Stay at the Top of the Healthcare Sector?

Stocks likely to beat and miss their earnings expectations - BofA

Goldman's debt issuers stocks basket

Artisan Global Value Fund Q1 2024 Commentary

ACGL

AMAT

AMGN

AMZN

APTV

AVGO

CARR

CBRE

CHRW

CHTR

COSM

CTLT

ENPH

FICO

FOXA

GEHC

GGROW

HDELY

HLBZF

INTC

KLAC

KVUE

MELI

MSFT

NCLH

NTNX

NWSA

NXPI

ORCL

PDCO

RBGLY

RBGPF

SCHW

SNPS

SOPH

TRGP

TRMB

TTWO

TWLO

VLTO

XRAY

ZBRA

Press Releases

Henry Schein Reports Fourth-Quarter and Full-Year 2023 Financial Results and Introduces 2024 Financial Guidance

Ethisphere Names Henry Schein as One of the 2024 World's Most Ethical Companies® for 13th Consecutive Year

Henry Schein Presents THRIVELIVE 2024

Viome Is Partnering with Henry Schein to Provide Better Access to Oral Health Pro™ With CancerDetect™

Henry Schein Completes Acquisition of Majority Interest of TriMed, Inc.

Henry Schein Announces Appointment of Three New Members to the Company's Executive Management Committee

Henry Schein to Webcast First Quarter 2024 Conference Call on Tuesday, May 7, 2024 at 10:00 A.M. ET